Intelligent bio solutions inc. reports fiscal 2023 fourth quarter and full year financial results and operational highlights

- combined full-year revenue and government support income increased 355% year-over-year - - received guidance from u.s. fda on a regulatory pathway for its intelligent fingerprinting drug screening cartridge - - granted 13 th patent following award of u.k. patent relating to dsr-plus cartridge reader - - recently secured 8 new customers just two months into product launch in australia - new york, aug. 24, 2023 (globe newswire) -- intelligent bio solutions inc. ("intelligent bio solutions," "inbs" or the "company") (nasdaq: inbs), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for its fiscal fourth quarter and full-year ended june 30, 2023, and provided a business update. “in the 2023 fiscal year, we maintained rapid expansion of our customer footprint, successfully entering the australian market with accelerated uptake,” said harry simeonidis, president and chief executive officer of intelligent bio solutions.
inbs Ratings Summary
inbs Quant Ranking